Analysts say these ASX 300 shares are buys with 14% to 25% upside

Great returns could be on the cards for buyers of these shares according to analysts.

| More on:
Two brokers analysing stocks.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Are you on the lookout for some new additions to your portfolio in December?

If you are, it could pay to look at the two ASX 300 shares that brokers have just put buy ratings on.

Here's what they are saying about them:

Monash IVF Group Ltd (ASX: MVF)

Morgans thinks that this ASX 300 share could be fertile ground to grow an investment.

The broker likes Monash IVF, which is one of the largest fertility clinic operators in the country, due to its attractive valuation and strong structural demand.

Commenting on its recent trading update, the broker said:

MVF has provided a trading update at its AGM for performance YTD (up to October) and has provided guidance for 1H25 of underlying NPAT between $15.5-16.0m and continues to expect both revenue and underlying NPAT growth in FY25. Australian ARS industry cycles were weak in July and August, particularly in VIC, QLD and SA, but have since rebounded to see industry stimulated cycle growth up 2.9%. MVF is tracking slightly below industry, although maintaining market share on the pcp. The South East Asian business continues to gather momentum with strong growth YTD following a strong 2H24.

Despite continued cost pressures, MVF has maintained EBITDA margins YTD largely through patient price increases. We have made minor downward revisions to our earnings but continue to see strong structural demand drivers for MVF, we maintain our Add recommendation with a $1.50 price target (was $1.54).

Based on its current share price of $1.20, this price target implies potential upside of 25% for investors over the next 12 months.

NIB Holdings Limited (ASX: NHF)

This morning, Goldman Sachs has retained its buy rating and $6.50 price target on this health insurance company's shares.

This follows the release of quarterly data which showed that participation rates have improved. Outside this, the broker believes NIB is a buy due to its defensive earnings and favourable trading conditions. It said:

NHF is a private health insurer with operations across Australian residents health insurance, New Zealand health insurance, International health insurance and Travel. We are Buy-rated on NHF given: 1) It offers defensive exposure to the private health insurance sector 2) The claims environment (utilisation / inflation) is generally manageable albeit until recently 3) NHF policyholder growth has been better than industry, 4) Expense buffers available to support margins and 5) Strong approved rate increases.

Based on its current share price of $5.70, Goldman's price target implies potential upside of 14% over the next 12 months. The broker also expects a 4.5% dividend yield in FY 2025.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended NIB Holdings. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

A young man wearing a black and white striped t-shirt looks surprised.
Broker Notes

These ASX 200 shares could rise 25% to 80%

Analysts think big returns could be on offer from these shares.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A group of three miners in hard hats and high visibility vests confer at a rocky mining site.
Broker Notes

Up 66% in a year, just how much more upside does Macquarie tip for Perseus Mining shares?

Just how much higher might Perseus Mining shares soar? Here’s what Macquarie had to say about the ASX 200 gold…

Read more »

Rising share price chart.
Broker Notes

Why this exciting ASX 200 share could rise almost 50%

Bell Potter has good things to say about this biopharmaceutical company.

Read more »

Buy and sell written on silver cubes on a stock market chart.
Broker Notes

2 buys and 2 sells in the ASX 200 financials sector: analysts

We reveal what the experts think of these ASX 200 financial shares.

Read more »

Person pointing at an increasing blue graph which represents a rising share price.
Broker Notes

These ASX 200 shares could rise 33% to 37%

Analysts at Morgans think these shares could deliver big returns.

Read more »

Female miner in hard hat and safety vest on laptop with mining drill in background.
Broker Notes

Experts reveal 2 buys and 1 sell in the ASX 200 materials sector

And they're not all mining companies, either.

Read more »

A smiling miner wearing a high vis vest and yellow hardhat does the thumbs up in front of an open pit copper mine.
Broker Notes

Why Macquarie expects this ASX All Ords copper stock to soar 48% in a year

Macquarie forecasts another big year of gains ahead for this ASX All Ords copper stock. But why?

Read more »